Targeting TGF-β overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade

Kidney International

Volumn 54, Issue 5, 1998, Pages 1570-1580

  Peters, Harm ^a   Border, Wayne A ^a   Noble, Nancy A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Enalapril; Fibrosis; Glomerulonephritis; Losartan; Transforming growth factor

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FIBRONECTIN; LOSARTAN; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE INHIBITOR; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; GENE TARGETING; GLOMERULUS; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; KIDNEY FIBROSIS; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

EID: 0031727915     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1998.00164.x     Document Type: Article

References (47)

1. BORDER WA, NOBLE NA: Transforming growth factor-β in tissue fibrosis. N Engl J Med 331:1286-1292, 1994
2. NOBLE NA, BORDER WA: Angiotensin II in renal fibrosis: Should TGF-β rather than blood pressure be the therapeutic target? Semin Nephrol 17:455-466, 1997
3. BORDER WA, NOBLE NA: Interactions of TGF-β and angiotensin II in renal fibrosis. Hypertension S31:181-188, 1998
4. BORDER WA, OKUDA S, LANGUINO LR, SPORN MB, RUOSLAHTI E: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta-1. Nature 346:371-374, 1990
5. BORDER WA, NOBLE NA, YAMAMOTO T, HARPER JR, YAMAGUCHI Y, PIERSCHBACHER MD, RUOSLAHTI E: Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 360:361-364, 1992
6. ISAKA Y, BREES DK, IKEGAYA K, KANEDA Y, IMAI E, NOBLE NA, BORDER WA: Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med 2:418-423, 1996
7. ISAKA Y, FUJIWARA Y, UEDA N, KANEDA Y, KAMADA T, IMAI E: Glomerulosclerosis induced by in vivo transfection of transforming growth factor-β or platelet-derived growth factor into the rat kidney. J Clin Invest 92:2597-2601, 1993
8. KOPP JB, FACTOR VM, MOZES M, NAGY P, SANDERSON N, BÖTTINGER EP, KLOTMAN PE, THORGEIRSSON SS: Transgenic mice with increased plasma levels of TGF-β1 develop progressive renal disease. Lab Invest 74:991-1003, 1996
9. ICHIKAWA I: Will angiotensin II receptor antagonists be renoprotective in humans? Kidney Int 50:684-492, 1996
10. KIM S, OHTA K, HAMAGUCHI A, OMURA T, YUKIMURA T, MIURA K, INADA Y, WADA T, ISHIMURA Y, CHATANI F, IWAO H: Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 24:195-204, 1994
11. PARVING HH, HOMMEL E, DAMKJAER NIELSEN M, GIESE J: Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy. BMJ 299:533-536, 1989
12. YAMAMOTO T, MUNDY CA, WILSON CB, BLANTZ RC: Effect of mesangial cell lysis and proliferation on glomerular hemodynamics in the rat, Kidney Int 40:705-713, 1991
13. BAGCHUS WM, HOEDEMAEKER PJ, ROZING J, BAKKER WW: Glomerulonephritis induced by monoclonal anti-thy 1.1 antibodies. Lab Invest 55:680-687, 1986
14. TODD PA, HEEL RC: Enalaprin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 31:198-248, 1986
15. SMITH RD, CHIU AT, WONG PC, HERBLIN WF, TIMMERMANS PBWM: Phamacology of nonpeptide angiotenisin II receptor antagonists. Annu Rev Pharmacol Toxicol 32:135-165, 1992
16. RYAN MJ, BOUCHER DM, COHEN DM, OLSZEWSKI BJ, SINGER RM, SMITH RD, KAPLAN HR: Antihypertensive profile of the angiotensin-converting enzyme inhibitors CI-906 and CI-907. Fed Proc 43:1330-1332, 1984
17. LAFAYETTE RA, MAYER G, PARK SK, MEYER TW: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 90:766-771, 1992
18. OKUDA S, NAKAMURA T, YAMAMOTO T, RUOSLAHTI E, BORDER WA: Dietary protein restriction rapidly reduces transforming growth factor β1 expression in experimental glomerulonephritis. Proc Natl Acad Sci USA 88:9765-9769, 1991
19. OKUDA S, LANGUINO LR, RUOSLAHTI E, BORDER WA: Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis: Possible role in expansion of the mesangial extracellular matrix. J Clin Invest 86:453-462, 1990
20. RENNARD SI, BERG R, MARTIN GR, FOIDART JM, ROBEY PG: Enzyme-linked immunoassay (ELISA) for connective tissue components. Anal Biochem 104:205-214, 1980
21. FORT P, MARTY L, PIECHACZYK M, SABROUTY SE, DANI C, JEANTEUR PH, BLANCHARD JM: Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucl Acids Res 13:1431-1442, 1985
22. DERYNCK R, JARRETT A, CHEN EY, GOFDDEL DV: The murine transforming growth factor-B precursor. J Biol Chem 261:4377-4379, 1986
23. SCHWARZBAUER JE, TAMKUN JW, LEMISCHKA IR, HYNES RO: Three different fibronectin mRNAs arise by alternative splicing within the coding region. Cell 35:421-431, 1983
24. ZEHEB R, GELEHRTER TD: Cloning and sequencing of cDNA for the rat plasminogen activator inhibitor-1. Gene 73:459-468, 1988
25. REYES AA, PUKERSON ML, KARL I, KLAHR S: Dietary supplementation with L-arginine ameliorates the progression of renal disease in rats with subtotal nephrectomy. Am J Kidney Dis 20:168-176, 1992
26. PETERS H, BORDER WA, NOBLE NA: Low protein diet and L-arginine supplementation produce additive therapeutic effects on mesangiproliferative glomerunephrtitis in the rat. (abstract) J Invest Med 45:277A, 1997
27. NISHIMURA M, OKAMURA M, KONISHI Y, INOUE K, YOUNG CK, YOSHIOKA T, NEGORO N, INOUE T, KANAYAMA Y: Effect of treatment with ACE inhibitor (ACEI) on TGF-beta gene expressions in renal biopsy from patients with IgA nephropathy. (abstract) J Am Soc Nephrol 6:397, 1995
28. ELTAYEB B, ALZAHABI B, ZIYADEH FN, ROHDE R, LEWIS EJ, SHARMA K: Effects of captopril on serum levels of TGF-β1 in insulin-dependent diabetic patients. (abstract) J Am Soc Nephrol 8:110A, 1997
29. ANDERSON S, RENNKE HG, BRENNER BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77:1993-2000, 1986
30. MATSUSAKA T, HYMES J, ICHIKAWA I: Angiotensin in progressive renal diseases: Theory and practice. J Am Soc Nephrol 7:2025-2043, 1996
31. IKOMA M, KAWAMURA T, KAKINUMA Y, FOGO A, ICHIKAWA I: Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 40:195-202, 1991
32. KIYAMA S, NANISHI F, TOMOOKA S, OKUDA S, ONOYAMA K, FUJISHIMA M: Inhibitory effects of antihypertensive drugs on mesangial cell proliferation after anti-thymocyte serum (ATS)-induced mesangiolysis in spontaneously hypertensive rats. Life Sci 54:1891-1900. 1994
33. ZOJA C, ABBATE M, CORNA D, CAPITANIO M, DONADELLI R, BRUZZI I, OLDROYD S, BENIGNI A, REMUZZI G: Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-β in experimental mesangioproliferative glomerulonephritis. Am J Kidney Dis 31:453-463, 1998
34. CAMPBELL DJ, KLADIS A, VALENTIJN AJ: Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol 26:233-240, 1995
35. BROSNIHAN KB, LI P, FERRARIO CM: Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 27:523-528, 1996
36. SEYEDI N, XU X, NASJLETTI A, HINTZE TH: Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 26:164-170, 1995
37. 2 production in conscious rats. J Clin Invest 97:1978-1982, 1996
38. LUI YH, YANG XP, SHAROV VG, NASS O, SABBAH HN, PETERSON E, CARRETERO OA: Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptor. J Clin Invest 99:1926-1935, 1997
39. GREENL EL, KRIN S, HOSILTTER TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 98:1063 1068, 1996
40. AZIZI M, CHAIELLIER G, GUYENE T-T, MURILIA-GEOFFROY U, MINARD J: Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 92:825-834, 1995
41. WOLF G, HABERSTROH U, NEILSON EG: Angiotensin II stimulates the proliferation and biosynthesis of type 1 collagen in cultured murine mesangial cells. Am J Pathol 140:95-107, 1992
42. RAY PE, AQUILERA G, KOPP JB, HORIKOSHI S, KLOTMAN PE: Angiotensin II receptor-mediated proliferation of cultured human fetal mesangial cells. Kidney Int 40:764 771, 1991
43. ITOH H, MUKOYAMA M, PRAII RE, GIBBONS GH, DZAU VJ: Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 91:2268-2274, 1993
44. KAGAMI S, BORDER WA, MILLER DE, NOBLE NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 93:2431-2437, 1994
45. BATTEGAY EJ, RAINES EW, SFIFERT RA, BOWEN-POPE DF, ROSS R: TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 63:515-524, 1990
46. HABERSTROH U, ZAHNER G, DISSER M, THAISS F, WOLF G, STAHL RAK: TGF-β stimulates rat mesangial cell proliferation in culture: Role of PDGF b-receptor expression. Am J Physiol 264:F199-F205, 1993
47. STOUFFER GA, OWENS GK: TGF-β promotes proliferation of cultured SMC via both PDG-AA-dependent and PDGF-AA-independent mechanisms. J Clin Invest 93:2048-2055, 1994